Scientists test Triple-Threat drug cocktail in fight against tough cancers
NCT ID NCT04495257
Summary
This early-stage study is testing a new three-drug combination for people with advanced melanoma or kidney cancer. The main goal is to find a safe and tolerable dose of the new drug, APX005M, when given with two existing immunotherapy drugs. Researchers will enroll about 26 patients who have not yet received immunotherapy to see how well the body handles this treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale Cancer Center
New Haven, Connecticut, 06519, United States
-
Yale New Haven Hospital
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.